

July 11, 2025



# FibroBiologics to Present at the Advanced Wound Care Summit USA

HOUSTON, July 11, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O'Heeron, will present at the Advanced Wound Care Summit USA in Boston, Massachusetts, on July 15, 2025. The presentation will include recent research advances using fibroblast-based technology for indications such as wound healing and psoriasis.

"The Advanced Wound Care Summit is an ideal forum to showcase how FibroBiologics is pioneering the next generation of wound healing through our fibroblast-based technology," said Mr. O'Heeron. "Our CYWC628 therapy represents a fundamentally different approach to treating diabetic foot ulcers, one that taps into the body's natural regenerative processes rather than simply managing symptoms. With our Phase 1/2 clinical trial set to kick off later this year, we are poised to deliver potentially transformative outcomes for patients with limited treatment options and high recurrence rates."

## Details of the presentation are as follows:

**Date:** Tuesday, July 15, 2025

**Time:** 2 p.m. ET

**Location:** Marriott Courtyard Boston Downtown

The Advanced Wound Care Summit, taking place July 15–17, will bring together global leaders in wound care innovation, clinical research, and advanced therapeutics to address unmet needs in chronic wound management. With a focus on accelerating product development and enhancing patient outcomes, the summit will feature keynote presentations, interactive panels, and strategic networking opportunities.

For more information, please visit FibroBiologics' [website](#) or email FibroBiologics at [info@fibrobiologics.com](mailto:info@fibrobiologics.com).

## Cautionary Statement Regarding Forward-Looking Statements

This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning plans for, and the anticipated timing of the initiation of and results from, FibroBiologics' current and future preclinical studies, clinical trials and research and development programs, and the potential clinical benefits of fibroblasts and fibroblast-derived materials. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions

concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, [www.sec.gov](http://www.sec.gov). These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of our R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.

## **About FibroBiologics**

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 275+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit [www.FibroBiologics.com](http://www.FibroBiologics.com).

### **General Inquiries:**

[info@fibrobiologics.com](mailto:info@fibrobiologics.com)

### **Investor Relations:**

Nic Johnson

Russo Partners

(212) 845-4242

[fibrobiologicsIR@russopr.com](mailto:fibrobiologicsIR@russopr.com)

### **Media Contact:**

Liz Phillips

Russo Partners

(347) 956-7697

[Elizabeth.phillips@russopartnersllc.com](mailto:Elizabeth.phillips@russopartnersllc.com)



Source: FibroBiologics, Inc.